Skip to search formSkip to main contentSkip to account menu

Nelipepimut-S

Known as: L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl-, E75 Peptide, Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide 
A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta‐analysis
2018
2018
Polyactin A is a novel and potent immunological adjuvant for peptide‐based cancer vaccine☆
2017
2017
A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice
Abstract E75 (HER-2/neu-369–377), is an immunogenic peptide which is highly expressed in breast cancer patients. The purpose of… 
2011
2011
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine
The authors are conducting clinical trials of the HER‐2/neu E75‐peptide vaccine in clinically disease‐free breast cancer (BC… 
Highly Cited
2009
Highly Cited
2009
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Purpose: HER2/neu, a source of immunogenic peptides, is expressed in >75% of breast cancer patients. We have conducted clinical… 
Highly Cited
2007
Highly Cited
2007
Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.
We used the Luminex assay to compare serum cytokine profiles of breast cancer patients (BCa) to healthy controls, node-positive… 
2007
2007
Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to a Preventive HER2/neu Vaccine-Based Immunotherapy for Breast Cancer: A Pilot Study
BackgroundOngoing cancer vaccine trials are limited by the inability of immunologic assays to monitor clinically relevant… 
2006
2006
Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients
Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their… 
2006
2006
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine
We are conducting clinical trials of the E75 peptide as a vaccine in breast cancer (BrCa) patients. We assessed T cell… 
2004
2004
Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients
HER2/neu is a proto-oncogene and a member of the epidermal growth factor receptor family of proteins that is overexpressed in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)